{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-083274","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2026-07-14T10:04:48+00:00","discovered_at":"2026-07-14T10:10:00.205146+00:00","generated_at":"2026-07-14T10:10:05.729880+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alto Neuroscience raises ~$93.9M in registered direct offering of 3.78M shares at $26.48/share","bullets":["Offering of 3,776,436 shares of common stock at $26.48 per share, expected to close July 14, 2026.","Net proceeds estimated at $93.9M after underwriting discounts and expenses.","Proceeds to accelerate clinical development of ALTO-207, including additional Phase 3 trial for treatment-resistant depression.","Joint book-runners: BofA Securities, Stifel, William Blair, Robert W. Baird; co-managers: JonesTrading, H.C. Wainwright."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-083274","json":"https://secwatch.observer/filing/0001104659-26-083274.json","markdown":"https://secwatch.observer/filing/0001104659-26-083274.md","text":"https://secwatch.observer/filing/0001104659-26-083274.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000110465926083274/0001104659-26-083274-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000110465926083274/tm2620328d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-14T10:10:05.729880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}